Back

Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims

2 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 1 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Tatsiana Vaitsiakhovich

Bayer AG, Berlin (Germany)

13 More presentations in this session

Presentation thumbnail
Associate Professor T. Novikova (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Doctor L. Bergamaschi (Bologna, IT)
Abstract Slides
Presentation thumbnail
Ms I. Palau (London, GB)
Abstract
Presentation thumbnail
Doctor Y. Gue (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Professor P. Hjemdahl (Stockholm, SE)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

The Event

Event poster

ESC Congress 2019

2 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources